4basebio UK Societas Director/PDMR Shareholding

 
TIDM4BB 
 
01 July 2021 
 
                             4basebio UK Societas 
                                (the "Company") 
                              Director's Dealing 
 
4basebio UK Societas (AIM: 4BB), the specialist life sciences group focused on 
exploiting its intellectual property in the field of gene therapies and DNA 
vaccines, announces that, on 1 July 2021, Heikki Lanckriet, chief executive 
officer, acquired 3,450 ordinary shares at an average price of 467 pence per 
share on behalf of persons closely associated with him. 
 
As a result of the acquisition of ordinary shares, Heikki Lanckriet's 
beneficial holding, including shares held by persons closely associated with 
him, comprises 1,243,453 ordinary shares representing 10.10 per cent. of the 
Company's issued share capital. 
 
This announcement contains inside information for the purposes of Article 7 of 
EU Regulation 596/2014. 
 
For further enquiries, please contact: 
 
4basebio UK Societas                                       [phone] 
 
Heikki Lanckriet, CEO 
 
Cairn Financial Advisers LLP (Nominated                    [phone] 
Adviser) 
 
Jo Turner / Sandy Jamieson 
 
finnCap Ltd (Broker)                                       [phone] 
 
Geoff Nash/Richard Chambers/Charlotte 
Sutcliffe 
 
Walbrook PR                                                [phone] 
 
Anna Dunphy / Paul McManus          Mob: [phone] 
                                                                           893 
 
 
Notification and public disclosure of transactions by persons discharging 
managerial responsibilities and persons closely associated with them 
 
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 
596/2014 
 
1.        Details of the person discharging managerial responsibilities/person 
closely associated 
 
a.        Name                                                    Heikki 
Lanckriet 
 
2.        Reason for notification 
 
a.        Position/Status                                   Chief Executive 
Officer 
 
b.        Initial notification/ Amendment    Initial 
 
3.        Details of the issuer, emission allowance market participant, auction 
platform, auctioneer or auction monitor 
 
a.        Name                                                    4basebio UK 
Societas 
 
b.        LEI 
2138005D5SAG8FIR6G91 
 
4.        Details of the transaction(s): section to be repeated for (i) each 
type of instrument; (ii) each type of transaction; (iii) each date; and (iv) 
each place where transactions have been conducted 
 
a.        Description of the financial instrument, type Ordinary Shares of 
instrument 
 
Identification Code                            ISIN: GB00BLD8ZL39 
 
 
b.        Nature of the transaction                Acquisition of ordinary 
shares 
 
 
c.         Price(s) and volume(s)       Volume(s)           Price (p) 
 
 
                a.        1,500                     467p 
                b.             650                       467p 
                c.             650                       467p 
                d.             650                       467p 
 
d.        Aggregated information 
 
- Aggregated Volume                        3,450 
- Price                                                    467 pence per share 
 
 
e.        Date of the transaction                    1/7/2021 
 
 
f.         Place of the transaction London Stock Exchange, AIM 
 
 
 
END 
 
 

(END) Dow Jones Newswires

July 01, 2021 11:09 ET (15:09 GMT)